© 1996 by Oxford University Press
Journal of the National Cancer Institute, Vol. 88, No. 15, 1054-1059,
August 7, 1996
© 1996 Oxford University Press
Loss of Tumor Marker-Immunostaining Intensity on Stored Paraffin Slides of Breast Cancer
Department of Pathology, Beth Israel Hospital, and Harvard Medical School Boston, MA
Stuart J. Schnitt, M.D., Department of Pathology, Beth Israel Hospital, 330 Brookline Ave., Boston, MA 02215.
BACKGROUND:: We previously observed decreased p53 immunostaining over time in paraffin-embedded sections of ductal carcinoma in situ of the breast of women; these sections had been stored on slides at room temperature. This observation suggests that slide storage adversely affects p53-immuno-staining intensity and could result in spurious negative staining for p53 in patient samples.
PURPOSE:: The goals of this study were to determine the time course and factors influencing loss of p53 immunoreactivity and to investigate whether a similar loss of reactivity occurs with other antigens commonly used to study breast cancer.
METHODS:: Serial sections cut from 12 formalin-fixed, paraffin-embedded, p53-positive invasive ductal carcinomas of the breast were stored on slides at room temperature or at 4 °C, with or without an additional paraffin coating, for 2, 4, 8, or 12 weeks. For each case, freshly cut slides from the same block (day 0) and stored slides were simultaneously stained for p53 by use of an automated immunostainer. Slides cut from formalin-fixed, paraffin-embedded breast carcinomas and stored for 12 weeks were also stained for factor VIII-related antigen (n = 12), estrogen receptor (ER) (n = 9), and Bcl-2 protein (n = 9). The staining intensity of all slides was assessed by visual microscopic examination and was also quantified by image analysis. Quantitative results were expressed as a percentage (mean ± standard error) of the staining intensity on day 0. Data were analyzed by the Friedman Repeated Measures Analysis of Variance on Ranks, with statistical significance set at two-sided P<.05.
RESULTS:: The intensity of p53 staining decreased over time in nine (75%) of the 12 cases studied. In three (or 25% of all cases studied) of the nine cases that showed decreased p53 staining, slides stored for 12 weeks were scored as p53 negative. Antigen loss on slides stored at 4 °C was significantly less than that on slides stored at room temperature at all time points (all P<.05). At 12 weeks, the average staining intensity of slides stored at 4 °C was 33.2% ± 9% of that on day 0 compared with 8.4% ± 3% of that on day 0 for slides stored at room temperature (P<.001). Paraffin coating of the sections did not significantly diminish antigen loss at either room temperature or 4 °C, except for slides stored at room temperature for 12 weeks. The intensity of factor VIII staining decreased in nine of 12 cases (average staining intensity, 37.3% ± 6% of that on day 0 at 12 weeks; P =.0001). The intensity of ER and Bcl-2 staining decreased in all nine cases studied at 12 weeks (average staining intensity, 14.0% ± 6% and 21.0% ± 4% of that on day 0, respectively; P =.0001 for each).
CONCLUSIONS AND IMPLICATIONS:: Slide storage, particularly at room temperature, results in substantial loss of p53 reactivity, with some p53-positive cases becoming p53 negative after 12 weeks of storage. Substantial loss of immunoreactivity for factor VIII, ER, and Bcl-2 occurs on slides stored at room temperature for 12 weeks. Storage of unstained slides for up to 12 weeks may lead to false-negative immunostaining for p53 and other antigens. [J Natl Cancer Inst 1996; 88: 1054–9]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Cankovic, R. C. Varney, L. Whiteley, R. Brown, R. D'Angelo, D. Chitale, and R. J. Zarbo The Henry Ford Production System: LEAN Process Redesign Improves Service in the Molecular Diagnostic Laboratory: A Paper from the 2008 William Beaumont Hospital Symposium on Molecular Pathology J. Mol. Diagn., September 1, 2009; 11(5): 390 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Sauter, J. Lee, J. M.S. Bartlett, D. J. Slamon, and M. F. Press Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations J. Clin. Oncol., March 10, 2009; 27(8): 1323 - 1333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Burns, Y. Li, C. A. Cheney, Y. Ou, L. L. Franlin-Pfeifer, N. Kuklin, and Z.-Q. Zhang Choice of Fixative Is Crucial to Successful Immunohistochemical Detection of Phosphoproteins in Paraffin-embedded Tumor Tissues J. Histochem. Cytochem., March 1, 2009; 57(3): 257 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Ramos-Vara, M. Kiupel, T. Baszler, L. Bliven, B. Brodersen, B. Chelack, S. Czub, F. D. Piero, S. Dial, E.J. Ehrhart, et al. Suggested guidelines for immunohistochemical techniques in veterinary diagnostic laboratories J Vet Diagn Invest, July 1, 2008; 20(4): 393 - 413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R A Walker, J M S Bartlett, M Dowsett, I O Ellis, A M Hanby, B Jasani, K Miller, and S E Pinder HER2 testing in the UK: further update to recommendations J. Clin. Pathol., July 1, 2008; 61(7): 818 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R A Walker Immunohistochemical markers as predictive tools for breast cancer J. Clin. Pathol., June 1, 2008; 61(6): 689 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Shanmugam, V. R. Katkoori, N. C. Jhala, W. E. Grizzle, G. P. Siegal, and U. Manne p53 Nuclear Accumulation and Bcl-2 Expression in Contiguous Adenomatous Components of Colorectal Adenocarcinomas Predict Aggressive Tumor Behavior J. Histochem. Cytochem., March 1, 2008; 56(3): 305 - 312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Blind, A Koepenik, M Pacyna-Gengelbach, G Fernahl, N Deutschmann, M Dietel, V Krenn, and I Petersen Antigenicity testing by immunohistochemistry after tissue oxidation J. Clin. Pathol., January 1, 2008; 61(1): 79 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Henson Back to the Drawing Board on Immunohistochemistry and Predictive Factors J Natl Cancer Inst, December 21, 2005; 97(24): 1796 - 1797. [Full Text] [PDF]
|
|
|
|
|
|
D. Atkins, K.-A. Reiffen, C. L. Tegtmeier, H. Winther, M. S. Bonato, and S. Storkel Immunohistochemical Detection of EGFR in Paraffin-embedded Tumor Tissues: Variation in Staining Intensity Due to Choice of Fixative and Storage Time of Tissue Sections J. Histochem. Cytochem., July 1, 2004; 52(7): 893 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Fergenbaum, M. Garcia-Closas, S. M. Hewitt, J. Lissowska, L. C. Sakoda, and M. E. Sherman Loss of Antigenicity in Stored Sections of Breast Cancer Tissue Microarrays Cancer Epidemiol. Biomarkers Prev., April 1, 2004; 13(4): 667 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W Hilbe, S Dirnhofer, F Oberwasserlechner, W Eisterer, K Ammann, T Schmid, G Hilbe, J Thaler, and E Woll Immunohistochemical typing of non-small cell lung cancer on cryostat sections: correlation with clinical parameters and prognosis J. Clin. Pathol., October 1, 2003; 56(10): 736 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Bernard and C. T. Wittwer Real-Time PCR Technology for Cancer Diagnostics Clin. Chem., August 1, 2002; 48(8): 1178 - 1185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Millward, W. Samowitz, C. T. Wittwer, and P. S. Bernard Homogeneous Amplification and Mutation Scanning of the p53 Gene Using Fluorescent Melting Curves Clin. Chem., August 1, 2002; 48(8): 1321 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Osman, E. Sherman, B. Singh, E. Venkatraman, M. Zelefsky, G. Bosl, H. Scher, J. Shah, A. Shaha, D. Kraus, et al. Alteration of p53 Pathway in Squamous Cell Carcinoma of the Head and Neck: Impact on Treatment Outcome in Patients Treated With Larynx Preservation Intent J. Clin. Oncol., July 1, 2002; 20(13): 2980 - 2987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Guidi, D. A. Berry, G. Broadwater, B. Helmchen, I. J. Bleiweiss, D. R. Budman, I. C. Henderson, L. Norton, and D. F. Hayes Association of Angiogenesis and Disease Outcome in Node-Positive Breast Cancer Patients Treated With Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil: A Cancer and Leukemia Group B Correlative Science Study From Protocols 8541/8869 J. Clin. Oncol., February 1, 2002; 20(3): 732 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Manne, B. D. Gary, D. K. Oelschlager, H. L. Weiss, A. R. Frost, and W. E. Grizzle Altered Subcellular Localization of Suppressin, a Novel Inhibitor of Cell-Cycle Entry, Is an Independent Prognostic Factor in Colorectal Adenocarcinomas Clin. Cancer Res., November 1, 2001; 7(11): 3495 - 3503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Guidi, D. A. Berry, G. Broadwater, M. Perloff, L. Norton, M. P. Barcos, and D. F. Hayes Association of Angiogenesis in Lymph Node Metastases With Outcome of Breast Cancer J Natl Cancer Inst, March 15, 2000; 92(6): 486 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Xie, S.W. Tsao, and Y.C. Wong Sex hormone-induced mammary carcinogenesis in female Noble rats: the role of androgens Carcinogenesis, August 1, 1999; 20(8): 1597 - 1606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.L. Pickett, G.J. Harber, A.A. DeCarlo, P. Louis, S. Shaneyfelt, L.J. Windsor, and M.K. Bodden 92K-GL (MMP-9) and 72K-GL (MMP-2) are Produced in vivo by Human Oral Squamous Cell Carcinomas and can Enhance FIB-CL (MMP-1) Activity in vitro Journal of Dental Research, July 1, 1999; 78(7): 1354 - 1361. [Abstract] [PDF]
|
|
|
|
|
|
M. D. Gammon, H. Hibshoosh, M. B. Terry, S. Bose, J. B. Schoenberg, L. A. Brinton, J. L. Bernstein, and W. D. Thompson Cigarette Smoking and Other Risk Factors in Relation to p53 Expression in Breast Cancer among Young Women Cancer Epidemiol. Biomarkers Prev., March 1, 1999; 8(3): 255 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Krenacs, A. W. Himmelmann, L. Quintanilla-Martinez, T. Fest, A. Riva, A. Wellmann, E. Bagdi, J. H. Kehrl, E. S. Jaffe, and M. Raffeld Transcription Factor B-Cell-Specific Activator Protein (BSAP) Is Differentially Expressed in B Cells and in Subsets of B-Cell Lymphomas Blood, August 15, 1998; 92(4): 1308 - 1316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Ross and J. A. Fletcher The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy Oncologist, August 1, 1998; 3(4): 237 - 252. [Abstract] [Full Text]
|
|
|
|
|
|
B. Royer, D. Cazals-Hatem, J. Sibilia, F. Agbalika, J.-M. Cayuela, T. Soussi, F. Maloisel, J.-P. Clauvel, J.-C. Brouet, and X. Mariette Lymphomas in Patients With Sjogren's Syndrome Are Marginal Zone B-Cell Neoplasms, Arise in Diverse Extranodal and Nodal Sites, and Are Not Associated With Viruses Blood, July 15, 1997; 90(2): 766 - 775. [Abstract] [Full Text] [PDF]
|
|